MedTrace Logo

Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control

NCT05098353 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-10-28

No results posted yet for this study

Summary

In this study, the task was to evaluate the effectiveness of prescribing small doses of quetiapine (25-75 mg) for bipolar patients in remission in order to relieve symptoms of impulsivity.

Conditions

  • Bipolar Affective Disorder

Interventions

DRUG

Quetiapine

25-75 mg per day for 6 weeks

Sponsors & Collaborators

  • Kazan State Medical University

    collaborator OTHER

  • Federal State Budgetary Institution V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Saint-Petersburg, Russia

    collaborator UNKNOWN

  • Federal Stare Budgetary Scientific Institution, Mental Health Research Center

    lead OTHER

Principal Investigators

  • Margarita A Morozova, PhD · Federal Stare Budgetary Scientific Institution, Mental Health Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-10
Primary Completion
2021-11-15
Completion
2021-12-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05098353 on ClinicalTrials.gov